Latest Headlines

  1. Mitsubishi UFJ Capital And AGC Sign A Mandate Agreement For The Technical Evaluation Of Drug Manufacturing For Investment Activities In Drug Discovery Start-ups 3/4/2025

    Mitsubishi UFJ Capital Co., Ltd.（Mitsubishi UFJ Capital; President: Takuro Kojima, Headquarters: Tokyo）and AGC Inc. (AGC; President: Yoshinori Hirai, Headquarters: Tokyo）have signed a mandate agreement for the technical evaluation of drug manufacturing, as part of Mitsubishi UFJ Capital's investment activities in drug discovery startups, etc.

  2. uBriGene Biosciences Submits Drug Master File For iPSC Reprogramming mRNA-LNP Kit 3/4/2025

    uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for its innovative iPSC Reprogramming mRNA-LNP Kit. This comprehensive regulatory submission details the manufacturing and characterizations of the iPSC Reprogramming mRNA-LNP Kit.

  3. The US FDA Grants Both Orphan Drug And Rare Pediatric Disease Designations To NEU-001 Of Neurenati For The Treatment Of Hirschsprung Disease 3/4/2025

     Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to NEU-001, a novel combination therapy utilizing a neurotrophic growth factor, for the treatment of Hirschsprung disease (HD).

  4. Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial 3/4/2025

    Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS.

  5. Laekna Announces IND Approval Of LAE120 (A Novel USP1 Inhibitor) For Treatment Of Advanced Solid Tumors By FDA 3/3/2025

    Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors.

  6. IDEAYA Biosciences Announces Collaboration With ATTMOS To Accelerate AI/ML-Enabled Drug Discovery For Unprecedented First-In-Class Oncology Targets 3/3/2025

    IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets.

  7. New Research Might Make An 'Undruggable' Target Druggable – Leading To New Cancer Drugs 2/28/2025

    Drug discovery researchers have made significant progress towards targeting a protein that is seen as a promising anticancer target but has, until now, been considered undruggable.

  8. Unravel Biosciences And COMBINED Brain Announce Large-Scale Drug Discovery Collaboration For Rare Neurological Diseases With High Unmet Need 2/27/2025

    Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company spun out of Harvard University to advance drugs for complex diseases and COMBINED Brain, a non-profit consortium devoted to speeding the path to clinical treatments for people with rare genetic neurological disorders by pooling efforts, studies, and data, today announced the initiation of a collaboration to identify promising drug candidates for clinical development across the more than 110 disorders represented by member patient advocacy groups in COMBINED Brain.

  9. Renovaro And BioSymetrics Announce Definitive Merger Agreement To Advance AI-Driven Biomarker Discovery And Precision Medicine 2/26/2025

    Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company.

  10. Enveda Gains Backing From Sanofi To Advance AI-Driven Drug Discovery To Clinical Trials Bringing Total Series C Financing To $150M 2/26/2025

    Enveda, a leading biotechnology company harnessing life’s chemistry to discover better medicines, today announced an investment from Sanofi, a leading healthcare company.